Mar 18 |
Precigen FY 2023 Earnings Preview
|
Mar 12 |
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
|
Mar 5 |
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
|
Feb 20 |
Precigen, Inc. (NASDAQ:PGEN): When Will It Breakeven?
|
Feb 12 |
Monday.com Reports Q4 Results, Joins AN2 TherapeuticsAnd Other Big Stocks Moving Lower In Monday's Pre-Market Session
|
Feb 6 |
Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
|
Feb 4 |
Insider Stock Buying Reaches US$1.72m On Precigen
|
Jan 20 |
Precigen: RRP Targeting With AdenoVerse Technology Platform
|
Jan 16 |
Precigen gets EU orphan drug status for respiratory tract drug
|
Jan 16 |
Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
|